Abstract | BACKGROUND: METHODS: We randomized 85 preterm infants ventilated at 7-14 d after birth to receive either late administration of surfactant (up to 5 doses) plus prolonged iNO or iNO alone. Large aggregate surfactant was isolated from daily tracheal aspirates (TAs) for measurement of SP-B content, total protein, and phospholipid (PL). RESULTS: Late administration of surfactant had minimal acute adverse effects. Clinical status as well as surfactant recovery and SP-B content in tracheal aspirate were transiently improved as compared to the controls; these effects waned after 1 d. The change in SP-B content with surfactant dosing was positively correlated with SP-B levels during treatment (r = 0.50, P = 0.02). CONCLUSION: Low SP-B values increased with calfactant administration, but the relationship of this response to SP-B levels suggests that degradation is a contributing mechanism for SP-B deficiency and surfactant dysfunction. We conclude that late therapy with surfactant in combination with iNO is safe and transiently increases surfactant SP-B content, possibly leading to improved short- and long-term respiratory outcomes.
|
Authors | Roberta L Keller, Jeffrey D Merrill, Dennis M Black, Robin H Steinhorn, Eric C Eichenwald, David J Durand, Rita M Ryan, William E Truog, Sherry E Courtney, Philip L Ballard, Roberta A Ballard |
Journal | Pediatric research
(Pediatr Res)
Vol. 72
Issue 6
Pg. 613-9
(Dec 2012)
ISSN: 1530-0447 [Electronic] United States |
PMID | 23037875
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Pulmonary Surfactant-Associated Protein B
- Pulmonary Surfactants
|
Topics |
- Humans
- Infant, Newborn
- Infant, Premature
- Pilot Projects
- Pulmonary Surfactant-Associated Protein B
(deficiency)
- Pulmonary Surfactants
(administration & dosage)
|